Medeon Biodesign (TPEx:6499) said today that it recently led and closed investments in an orthopedics startup and a company whose device was designed to treat benign prostatic hyperplasia (BPH).
Panther Orthopedics is a Silicon Valley startup working on fixation solutions for orthopedic extremity applications. Prodeon is a Taiwan-based company offering a simple, office-based treatment option for BPH patients who are seeking immediate relief from lower urinary tract symptoms (LUTS).
Panther Orthopedics’ FDA- 510(k) cleared Puma System is designed to treat orthopedic injuries with the benefits of screws and flexible fixation devices but without their shortcomings. The Puma body’s spring-like design provides initial and continuous compression without the need to overtighten, according to Taiwan-based Medeon Biodesign. The Puma system has been commercially available since November 2018.
Taiwan-based Prodeon’s investigational device, the Xflo expander system, is a novel, minimally invasive, office-based treatment that offers a simple option to conventional surgery or drugs for resolving BPH symptoms. The system successfully completed its first clinical use in Australia and the Republic of Georgia, according to Medeon Biodesign.
“Medeon has built an innovation platform that partners with physicians and entrepreneurs to solve unmet medical needs, by bringing innovative ideas from concept to commercialization,” said Medeon chairman & CEO Yue-Teh Jang in a news release. “With both the resources to fund projects and the capabilities to execute them, this platform combines the strengths of a traditional medtech venture capital firm and those of a medtech development firm. The two recent investments, in Panther Orthopedics and Prodeon, are perfect examples of executing this unique business model with a combination of funding, development expertise, manufacturing capabilities, and industry relations to accelerate medtech development.”